Letter to the editor: The impact of targeted rheumatoid arthritis pharmacologic treatment on mental health: A systematic review and meta-analysis: Reply.

We thank Dr Zembrzuska for her letter relating to our systematic review and network meta-analysis describing the impact of targeted pharmacological treatments on mental health outcomes in rheumatoid arthritis (RA) [1]. She highlights clearly the disparity in approach towards managing physical versus mental comorbidities in rheumatological practice. Approximately one in four people with RA will also have symptoms of depression [2] and there has been extensive recent research conducted by us here at King's College London, and by colleagues worldwide emphasising the impact common mental disorders such as symptoms of depression and anxiety may have on long-term physical health outcomes and treatment response in RA [3-6]. This article is protected by copyright. All rights reserved.